nach oben

Wiener klinische Wochenschrift

Erschienen in:

17.02.2021 | review article

Mutant strains of SARS-CoV-2 are more prone to infect obese patient: a review

verfasst von: Somorjit Singh Ningombam, Rakesh Kumar, Additional Professor Dr Pranay Tanwar

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2021

Einloggen, um Zugang zu erhalten

Summary

The current review critically analyzes obesity as an important risk factor for increased predisposition towards coronavirus disease 2019 (COVID-19), its severity and causal death in current pandemic. Countries with higher prevalence of exposed obese individuals experienced the highest number of mortalities. The analysis also proved that individuals having more adipose tissue in body have a higher level of angiotensin-converting enzyme 2 (ACE2), which is identified as functional receptor for COVID-19. Therefore, obese individuals are worse in condition because of a higher presence of adiposity increases the number of ACE2 expressing cells. Furthermore, in silico interactions of ACE2 and different variants of coronavirus 2 (CoV-2) spike S1 protein suggest that mutant strains are more infectious than wildtype as they bind to host ACE2 protein with high binding affinities. Certain specific cancers including cervical cancer, pancreatic and rectal adenocarcinomas have more expression of such receptors and pose additional risk to already immunocompromised cancer patients. This review emphasizes obesity, as the covert risk factor of COVID-19 infection and sensitizes about of calorie restrictions, immunity building and preventive measures.

Vorheriger Artikel Clinical manifestations of COVID-19 in the general population: systematic review

Nächster Artikel Sex and age differences in COVID-19 mortality in Europe

Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019;11:41. https://doi.org/10.3390/v11010041.CrossRefPubMedCentral

Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69. https://doi.org/10.1186/s12985-019-1182-0.CrossRefPubMedPubMedCentral

Zumla A, Hui DS, Perlman S. Middle east respiratory syndrome. Lancet. 2015;386:995–1007. https://doi.org/10.1016/S0140-6736(15)60454-8.CrossRefPubMedPubMedCentral

Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science. 2020;367:234–5. https://doi.org/10.1126/science.367.6475.234.CrossRefPubMed

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.CrossRefPubMedPubMedCentral

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207. https://doi.org/10.1056/NEJMoa2001316.CrossRefPubMedPubMedCentral

Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–23. https://doi.org/10.1002/jmv.25681.CrossRefPubMedPubMedCentral

Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020;92:408–17. https://doi.org/10.1002/jmv.25674.CrossRefPubMedPubMedCentral

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–36. https://doi.org/10.1080/22221751.2020.1719902.CrossRefPubMedPubMedCentral

10.

Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV‑2 transmission in ferrets. Nat Microbiol. 2020;3:1–8. https://doi.org/10.1038/s41564-020-00835-2.CrossRef

11.

Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020;56:106114. https://doi.org/10.1016/j.ijantimicag.2020.106114.CrossRefPubMedPubMedCentral

12.

Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV‑2 infection. Antiviral Res. 2020;29:104811. https://doi.org/10.1016/j.antiviral.2020.104811.CrossRef

13.

Hong SI, Ryu BH, Chong YP, Lee S, Kim S, Kim HC, et al. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β‑1b. Int J Antimicrob Agents. 2020; https://doi.org/10.1016/j.ijantimicag.2020.106052.CrossRefPubMedPubMedCentral

14.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2034577.CrossRefPubMedPubMedCentral

15.

Rose PW, Beran B, Bi C, Bluhm WF, Dimitropoulos D, Goodsell DS, et al. The RCSB Protein Data Bank: redesigned web site and web services. Nucleic Acids Res. 2010;39:D392–D401. https://doi.org/10.1093/nar/gkq1021.CrossRefPubMedPubMedCentral

16.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV‑2 by full-length human ACE2. Science. 2020;367:1444–8. https://doi.org/10.1126/science.abb2762.CrossRefPubMedPubMedCentral

17.

Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein–protein docking. Nat Protoc. 2017;12:255–78. https://doi.org/10.1038/nprot.2016.169.CrossRefPubMedPubMedCentral

18.

Kumar R, Saran S. Structure, molecular dynamics simulation, and docking studies of Dictyostelium discoideum and human STRAPs. J Cell Biochem. 2018;119:7177–91. https://doi.org/10.1002/jcb.26840.CrossRefPubMed

19.

Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis. 1997;18:2714–23. https://doi.org/10.1002/elps.1150181505.CrossRefPubMed

20.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMed

21.

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382:2012–22. https://doi.org/10.1056/NEJMoa2004500.CrossRefPubMed

22.

Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;23:1–2. https://doi.org/10.1038/s41574-020-0364-6.CrossRef

23.

Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020; https://doi.org/10.2139/ssrn.3556658.CrossRefPubMedPubMedCentral

24.

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell LF, Chernyak Y, Tobin K, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv. 1. 2020. https://doi.org/10.1101/2020.04.08.20057794.CrossRef

25.

Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus‑2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020; https://doi.org/10.1002/oby.22831.CrossRefPubMed

26.

Lighter J, Phillips M, Hochman S. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020; https://doi.org/10.1093/cid/ciaa415.CrossRefPubMed

27.

Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. https://doi.org/10.1016/j.metabol.2020.154244.CrossRefPubMedPubMedCentral

28.

Zhou YJ, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.04.027.CrossRefPubMedPubMedCentral

29.

Huang JF, Wang XB, Zheng KI, Liu WY, Chen JJ, George J, et al. Obesity hypoventilation syndrome and severe COVID-19. Metabolism. 2020;108:154249. https://doi.org/10.1016/j.metabol.2020.154249.CrossRefPubMedPubMedCentral

30.

Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, Fermín-Martínez CA, Naveja JJ, Aguilar-Salinas CA. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. MedRxiv.1. 2020. https://doi.org/10.1101/2020.04.20.20072223.CrossRef

31.

Murugan AT, Sharma G. Obesity and respiratory diseases. Chronic Respir Dis. 2008;5:233–42. https://doi.org/10.1177/1479972308096978.CrossRef

32.

Li J, Lai D, Wu D. Laparoscopic Roux-en‑Y gastric bypass versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities: a systematic review and meta-analysis. OBES SURG. 2016;26:429–42. https://doi.org/10.1007/s11695-015-1996-9.CrossRefPubMed

33.

Kyrou I, Randeva HS, Tsigos C, Kaltsas G, Weickert MO. Clinical problems caused by obesity. Endotext [Internet]. South Dartmouth (MA): MDtext.com. 2018. https://www.ncbi.nlm.nih.gov/books/NBK278973/. PMID: 25905207.

34.

Polovina S, Micić D, Bjelović M, Šumarac-Dumanović M, Kendereški A. Metabolic surgery and obesity related comorbidities. Vojnosanit Pregl. 2018;75:213–8. https://doi.org/10.2298/VSP160508340P.CrossRef

35.

Scott HA, Wood LG, Gibson PG. Role of obesity in asthma: mechanisms and management strategies. Curr Allerg Asthma Rep. 2017;17:53. https://doi.org/10.1007/s11882-017-0719-9.CrossRef

36.

Nigatu YT, Reijneveld SA, de Jonge P, van Rossum E, Bültmann U. The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: the lifelines cohort study. PLoS ONE. 2016;11:e148871. https://doi.org/10.1371/journal.pone.0148871.CrossRefPubMedPubMedCentral

37.

Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin. 2018;102:13–33. https://doi.org/10.1016/j.mcna.2017.08.004.CrossRef

38.

Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187–93. https://doi.org/10.1001/jama.289.2.187.CrossRefPubMed

39.

Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24–32. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?.CrossRefPubMed

40.

Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–90. https://doi.org/10.1001/jama.290.14.1884.CrossRefPubMed

41.

Grover SA, Kaouache M, Rempel P, Joseph L, Dawes M, Lau DC, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diab Endocrinol. 2015;3:114–22. https://doi.org/10.1016/S2213-8587(14)70229-3.CrossRef

42.

Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E4. https://doi.org/10.3760/cma.j.cn112148-20200220-00105.CrossRef

43.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Inter J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017.CrossRef

44.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV‑2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7. https://doi.org/10.1016/S1470-2045(20)30096-6.CrossRefPubMedPubMedCentral

45.

Halpin DM, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV‑2 infection? Lancet Respir Med. 2020;8:436–8. https://doi.org/10.1016/S2213-2600(20)30167-3.CrossRefPubMedPubMedCentral

46.

Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV‑2. J Endocrinol Invest. 2020;43:867–9. https://doi.org/10.1007/s40618-020-01236-2.CrossRefPubMedPubMedCentral

47.

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV‑2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.CrossRefPubMedPubMedCentral

48.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60. https://doi.org/10.1038/s41569-020-0360-5.CrossRefPubMed

49.

Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J, et al. Two Things about COVID-19 Might Need Attention. Preprints 2020, 2020020315. https://doi.org/10.20944/preprints202002.0315.v1.

50.

Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185–92. https://doi.org/10.1007/s11684-020-0754-0.CrossRefPubMed

51.

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97. https://doi.org/10.1038/nri2921.CrossRefPubMedPubMedCentral

52.

Ahn SY, Sohn SH, Lee SY, Park HL, Park YW, Kim H, et al. The effect of lipopolysaccharide-induced obesity and its chronic inflammation on influenza virus-related pathology. Environ Toxicol Pharmacol. 2015;40:924–30. https://doi.org/10.1016/j.etap.2015.09.020.CrossRefPubMed

53.

Karlsson EA, Hertz T, Johnson C, Mehle A, Krammer F, Schultz-Cherry S. Obesity outweighs protection conferred by adjuvanted influenza vaccination. mBio. 2016;7:e1144–e1116. https://doi.org/10.1128/mBio.01144-16.CrossRefPubMedPubMedCentral

54.

Xue KS, Stevens-Ayers T, Campbell AP, Englund JA, Pergam SA, Boeckh M, et al. Parallel evolution of influenza across multiple spatiotemporal scales. Elife. 2017;6:e26875. https://doi.org/10.7554/eLife.26875.CrossRefPubMedPubMedCentral

55.

Zheng Q, Cui G, Chen J, Gao H, Wei Y, Uede T, et al. Regular exercise enhances the immune response against microbial antigens through up-regulation of toll-like receptor signaling pathways. Cell Physiol Biochem. 2015;37:735–46. https://doi.org/10.1159/000430391.CrossRefPubMed

56.

Reidy PT, Yonemura NM, Madsen JH, McKenzie AI, Mahmassani ZS, Rondina MT, et al. An accumulation of muscle macrophages is accompanied by altered insulin sensitivity after reduced activity and recovery. Acta Physiol. 2019;226:e13251. https://doi.org/10.1111/apha.13251.CrossRef

57.

Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S, et al. Obesity increases the duration of influenza a virus shedding in adults. J Infect Dis. 2018;218:1378–82. https://doi.org/10.1093/infdis/jiy370.CrossRefPubMedPubMedCentral

58.

Honce R, Karlsson EA, Wohlgemuth N, Estrada LD, Meliopoulos VA, Yao J, et al. Obesity-related microenvironment promotes emergence of virulent influenza virus strains. mBio. 2020;11:e3341. https://doi.org/10.1128/mBio.03341-19.CrossRefPubMedPubMedCentral

59.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Intern J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017.CrossRef

60.

Korber B, Fischer W, Gnanakaran SG, Yoon H, Theiler J, Abfalterer W, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV‑2. BioRxiv. 2020; https://doi.org/10.1101/2020.04.29.069054.CrossRefPubMedPubMedCentral

61.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV‑2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20. https://doi.org/10.1038/s41586-020-2180-5.CrossRefPubMed

62.

WHO. Coronavirus disease 2019 (COVID-19). 2019. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 11 Jan 2020.

63.

WHO. Global Health Observatory (GHO) data. 2017. https://www.who.int/gho/ncd/risk_factors/overweight/en/. Accessed 11 Jan 2020.

64.

https://www.worldometers.info/coronavirus/. Accessed: 09.02.2021

65.

Chatterjee P, Nagi N, Agarwal A, Das B, Banerjee S, Sarkar S, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the current evidence. Indian J Med Res. 2020;151:147. https://doi.org/10.4103/ijmr.IJMR_519_20.CrossRefPubMedPubMedCentral

66.

Choon Lim Wong G, Narang V, Lu Y, Camous X, Nyunt MS, Carre C, et al. Hallmarks of improved immunological responses in the vaccination of more physically active elderly females. Exerc Immunol Rev. 2019;25:20–33.

Titel: Mutant strains of SARS-CoV-2 are more prone to infect obese patient: a review
verfasst von: Somorjit Singh Ningombam
Rakesh Kumar
Additional Professor Dr Pranay Tanwar
Publikationsdatum: 17.02.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 7-8/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01819-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7-8/2021

Personal protective equipment in the COVID-19 pandemic and the use of cooling-wear as alleviator of thermal stress

A retrospective comparison between influenza and COVID-19-associated ARDS in a Croatian tertiary care center

6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort

Sex and age differences in COVID-19 mortality in Europe

Sampling site matters when testing for COVID-19 after total laryngectomy: a case report

Establishing a telerehabilitation program for patients with Duchenne muscular dystrophy in the COVID-19 pandemic